Study of ASTX029 in Subjects With Advanced Solid Tumors

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

192

Participants

Timeline

Start Date

May 7, 2018

Primary Completion Date

August 1, 2024

Study Completion Date

March 3, 2025

Conditions
Solid Tumor, Adult
Interventions
DRUG

ASTX029

PiB

DRUG

ASTX029

Tablet

Trial Locations (31)

8028

Hospital Universitario Dexeus Site#241, Barcelona

10032

Columbia University Irving Medical Center - Herbert Irving Pavilion Site#112, New York

13005

Hôpital de la Timone Site #201, Marseille

19104

University of Pennsylvania-Abramson Cancer Center, Philadelphia

21231

The Sidney Kimmel Comprehensive Cancer Center Site#106, Baltimore

22031

Virginia Cancer Specialists Site#102, Fairfax

28027

Clinica Universidad de Navarra Madrid Site #242, Madrid

Clínica Universidad de Navarra Site#242, Madrid

48109

University of Michigan Rogel Cancer Center Site #113, Ann Arbor

52242

Holden Comprehensive Cancer Center, Iowa City

69373

Centre Léon Bérard Service d'Oncologie Médicale Site#202, Lyon

77030

The University of Texas MD Anderson Cancer Center Site#111, Houston

78229

START - South Texas Accelerated Research Therapeutics, LLC Site# 101, San Antonio

90033

University of Southern California Norris Comprehensive Cancer Center Site#114, Los Angeles

90048

Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute Site# 107, Los Angeles

91010

City of Hope Comprehensive Cancer Center, Duarte

92658

Hoag Memorial Hospital Site#115, Newport Beach

95817

University of California Davis Medical Center Site #121, Sacramento

97223

Providence Portland Medical Center Site #118, Portland

97239

Oregon Health and Science University Site #122, Portland

94115-2378

California Pacific Medical Center - Sutter Pacific Medical Center Site#117, San Francisco

06510

Smilow Cancer Hospital at Yale New Haven Site#105, New Haven

02114

Massachusetts General Hospital Site#103, Boston

02215

Dana Farber Cancer Institute Site#104, Boston

08028

Institut Català d'Oncologia Badalona Site#240, Barcelona

08035

Hospital Universitari Vall d'Hebrón Servicio de Oncología, Sala coordinación UITM Site#243, Barcelona

08916

Hospital Universitari Germans Trias i Pujol, Barcelona

M20 4BX

The Christie NHS Foundation Trust Site#220, Manchester

CB2 0QQ

Cambridge University Hospitals NHS Foundation Trust, Cambridge

NE7 7DN

The Newcastle Upon Tyne Hospitals NHS Foundation Trust Site #221, Newcastle upon Tyne

OX3 7LE

Churchill Hospital Site #224, Oxford

All Listed Sponsors
lead

Taiho Oncology, Inc.

INDUSTRY

NCT03520075 - Study of ASTX029 in Subjects With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter